Last reviewed · How we verify
Prothionamide — Competitive Intelligence Brief
phase 3
Polyphenol oxidase 2
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Prothionamide (Prothionamide) — IUATLD, Inc.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Prothionamide TARGET | Prothionamide | IUATLD, Inc | phase 3 | Polyphenol oxidase 2 | ||
| Ascaricid | hexylresorcinol | marketed | hexylresorcinol | Arachidonate 5-lipoxygenase, Tyrosinase, Polyphenol oxidase 2 | ||
| Arbutyne | ARBUTIN | marketed | Adenosine Receptor Agonist [EPC] | Tyrosinase, Polyphenol oxidase 2, Tyrosinase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Prothionamide CI watch — RSS
- Prothionamide CI watch — Atom
- Prothionamide CI watch — JSON
- Prothionamide alone — RSS
Cite this brief
Drug Landscape (2026). Prothionamide — Competitive Intelligence Brief. https://druglandscape.com/ci/prothionamide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing